Today: 4 April 2026
Beazley share price: what to watch before Monday as Zurich bid clock ticks
1 February 2026
2 mins read

Beazley share price: what to watch before Monday as Zurich bid clock ticks

London, Feb 1, 2026, 09:35 GMT — Market closed.

  • Beazley wrapped up Friday at 1,133 pence, edging up 0.1%.
  • New takeover-period filings on Friday revealed both long and short positions held by major banks.
  • Key dates coming up include Zurich’s decision deadline on Feb. 16 and Beazley’s earnings release on March 4.

Shares in Beazley (BEZG.L) closed Friday 0.1% higher at 1,133 pence, bouncing between 1,124 and 1,150 pence during the session as traders processed a fresh round of takeover-period filings. Investing.com

Markets are closed for the weekend, leaving all eyes on Monday’s open and the looming bidder decision. Zurich Insurance Group (ZURN.S) announced it has put forward an improved cash offer of 1,280 pence per share. The company must decide by 5 p.m. on Feb. 16 whether to make a firm offer or walk away; the deadline can only shift with Takeover Panel approval. Zurich warned: “There can be no certainty that any offer will be made,” pitching the bid as a strategic move to leverage Beazley’s footprint at Lloyd’s of London. Zurich

Friday’s close puts the stock around 150 pence—nearly 11%—under the proposal price. That gap leaves space for a better offer or a potential walk-away, keeping the trade edgy.

A Form 8.3 disclosure from Societe Generale, required for holders of 1% or more during an offer period, revealed total interests of 2.56% in Beazley shares and cash-settled derivatives as of Jan. 29. The report also showed short positions amounting to 0.56%. Alongside this, the filing detailed a series of modest buys and sells near £11.3 per share. Investegate

Barclays disclosed holding and/or controlling 1.20% of Beazley shares, alongside a 0.81% short position, according to an amended Form 8.5 notice from its exempt principal trading unit. The term “exempt principal trader” signals a market-maker role, usually maintaining hedged positions instead of directional bets. Lloyds Bank Investments

These disclosures happen regularly, but on a quiet day they can still shake things up. They also shed light on how much of the register is now driven by trading activity instead of long-term holders.

On Jan. 22, Beazley turned down Zurich’s offer of 1,280 pence per share, labeling it a significant undervaluation. The company said it remained “open-minded about all options to deliver value.” Zurich chose not to comment then. Reuters

Some analysts expect further price pressure or fresh bids. “You could well see other suitors come out given the quality of the Beazley business,” said Ben Cohen, an RBC Capital Markets analyst, highlighting other London-listed specialty firms like Hiscox and Lancashire Holdings. SP Global

Investors are waiting to see if the bidder makes a move in the coming days or if the Feb. 16 deadline passes quietly. They’ll also keep an eye on anything that could hit insurer earnings — like major catastrophe claims or weaker pricing — since that could quickly alter how much a buyer is willing to offer.

The outcome is clear-cut. Should Zurich back out, the deal premium might vanish quickly, leaving the stock to trade solely on its fundamentals again.

Looking ahead, the Feb. 16 decision deadline comes first. Beazley will then release its full-year 2025 results on March 4. The company’s AGM is set for April 22, with a first-quarter trading update due April 30. Beazley

Stock Market Today

  • Kestra Medical Director Raymond Cohen Boosts Stake with $200,000 Stock Buy
    April 3, 2026, 9:34 PM EDT. Kestra Medical Technologies director Raymond W. Cohen purchased 10,000 shares in an open-market transaction valued at nearly $200,000, increasing his direct ownership by 24.45% to 50,903 shares. Cohen, a seasoned medical device executive, acquired shares without involvement from trusts or derivatives. His purchases follow two prior buys totaling 27,000 shares since his board appointment in March 2025. Kestra's shares closed at $19.68 on March 26, 2026, down 17.2% over the past year. The $1.16 billion market cap company specializes in wearable cardiac devices like the ASSURE wearable cardioverter defibrillator, targeting high-risk cardiovascular patients. Cohen's continued investment signals confidence amidst Kestra's current valuation and ongoing efforts to integrate hardware and digital health services for better patient outcomes.
Weir Group PLC (WEIR.L) share price dips as BlackRock trims stake — what to watch next week
Previous Story

Weir Group PLC (WEIR.L) share price dips as BlackRock trims stake — what to watch next week

NIO stock heads into Monday after January deliveries jump 96% and pass 1 million mark
Next Story

NIO stock heads into Monday after January deliveries jump 96% and pass 1 million mark

Go toTop